You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme GBM high grade glioma a deadly and invasive brain tumor with no effective treatment Of the patients expected to be diagnosed with GBM this year most will succumb within a year There is an urgent demand for an efficac ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Hollow Fiber Catheter for Drug Delivery into the Prostate

    SBC: TWIN STAR TDS, LLC            Topic: 300

    DESCRIPTION provided by applicant The significance of the proposed research is based on the growing demand for healthcare resources to treat and manage prostatic disease particularly benign prostatic hyperplasia BPH and cancer Both the incidence and cost of treatment for BPH and its complications are growing rapidly with the aging U S population prostate cancer is the second leading cau ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Selection-driven plant metabolites for treatment of CNS diseases

    SBC: NAPROGENIX, INC.            Topic: 150

    DESCRIPTION provided by applicant This project aims to demonstrate that the evolution of plant biosynthetic pathways can be accelerated and driven to favor the synthesis of ligands which interact with a specific human target protein This is achieved by subjecting mutant plant cells to selection pressures favoring the survival of mutants with the phenotype of interest As an example this appro ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government